A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te‐Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee‐Chen Chang
Formatua: Artigo
Hizkuntza:ingelesa
Argitaratua: 2019
Sarrera elektronikoa:https://doi.org/10.1016/j.jtho.2019.10.003
http://www.jto.org/article/S1556086419335300/pdf
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

https://doi.org/10.1016/j.jtho.2019.10.003
http://www.jto.org/article/S1556086419335300/pdf

Antzeko izenburuak